Cell line · CVCL_B260
PC-9
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 154 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. PC-9. Cell lines, record CVCL_B260. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_B260
On this page
Cell line
As Cellosaurus gives it.
- Name
- PC-9
- Accession
- CVCL_B260
- RRID
- RRID:CVCL_B260
- Synonyms
- PC9, PC-9/S1, PC-9S1
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 45Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Lymph node (metastatic)
- Entry created
- 2012-06-06
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers154
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genetically engineered RNA inducers of proximity for protein regulation. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway. | Int J Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| m6A-dependent regulation of DGUOK-AS1 by RBM15 and HNRNPH1 in lung adenocarcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A USP15/KRT17-associated 13-gene prognostic cluster and functional validation in EGFR-mutant lung adenocarcinoma. | Respir Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bruceine E, a natural quassinoid from Brucea javanica, inhibits PARthanatos via targeting PARP1 in ischemic stroke. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 154
See all 154 papersRelatives46
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE PC-9-Cas9 | CVCL_F5QD | Cell lines | |
| Derived from it | HyCyte PC-9 KO-hTP53 | CVCL_F4FH | Cell lines | |
| Derived from it | HyCyte PC-9 hEGFR_p.L704N cell line | CVCL_F4KF | Cell lines | |
| Derived from it | HyCyte PC-9 stable cell line for hIL6 overexpression | CVCL_F4QD | Cell lines | |
| Derived from it | HyCyte PC-9-Luc | CVCL_E3IE | Cell lines | |
| Derived from it | HyCyte PC-9-Luc-GFP | CVCL_E3IF | Cell lines | |
| Derived from it | PC-14 | CVCL_1640 | Has a recorded problem | Cell lines |
| Derived from it | PC-9(gFGFR1) | CVCL_E8FK | Cell lines | |
| Derived from it | PC-9-GR-high | CVCL_S706 | Cell lines | |
| Derived from it | PC-9-GR-step | CVCL_S707 | Cell lines |
1 to 10 of 46
See all 46 relativesCell banks6
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_B260
GET https://conductscience.org/api/cell-lines/v1/CVCL_B260/papers?page=2